Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Table 1 Patient clinical characteristics

	TCHL study (n = 88)		Sequencing and pCR data available (n = 69)		Sequencing, PTEN and pCR data available (n = 45)
Characteristic	No. of patients	%	No. of patients	%	No. of patients	%
ER status
Negative	35	39.8	28	40.6	19	42.2
Positive	53	60.2	41	59.4	26	57.8
PR status
Negative	54	61.4	39	56.5	29	64.4
Positive	34	38.6	30	43.5	16	35.6
pCR
Yes	38	43.2	32	46.4	21	46.7
No	41	46.6	37	53.6	24	53.3
Unknown	9	10.2	37	53.6	24	53.3
Targeted therapy
Trastuzumab	38	43.2	30	43.5	21	46.7
Lapatinib	10	11.4	10	14.5	6	13.3
Trastuzumab + lapatinib	40	45.4	29	42	18	40
Age, years
<49	41	46.6	36	52.2	25	55.6
≥49	47	53.4	33	47.8	20	44.4
Tumour size, cm
≤5	56	63.6	46	66.7	30	66.7
>5	23	26.1	17	24.6	12	26.6
Unknown	9	10.3	6	8.7	3	6.7
N stage
N0	25	28.4	20	29	9	20
N1	50	56.8	40	58	31	68.9
N2	2	2.3	1	1.4	1	2.2
NX	2	2.3	2	2.9	1	2.2
Unknown	9	10.2	6	8.7	3	6.7
M stage
M0	88	100	69	100	45	100
Overall stage
IIA	30	34.1	26	37.7	12	26.6
IIB	31	35.2	25	36.2	21	46.7
IIIA	7	8	4	5.8	3	6.7
IIIB	10	11.4	8	11.6	6	13.3
IIIC	1	1.1	0	0	0	0
Unknown	9	10.2	6	8.7	3	6.7

Abbreviations: ER Oestrogen receptor, PR Progesterone receptor, pCR, Pathological complete response; PTEN Phosphatase and tensin homolog, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib
A total of 88 patients were enrolled in the TCHL phase II neoadjuvant study. After quality control, 74 patient samples were genotyped. Of these 74 samples, pCR data were available for 69 patients. Forty-five tumour samples had sufficient material for PTEN analysis. The clinical characteristics of these three patient groups are shown

ISSN: 1465-542X